Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride dissociates in body fluids into sodium and chloride ions, which are major determinants of extracellular fluid osmolality and volume. It maintains electrolyte balance, nerve impulse transmission, and muscle contraction.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment and prevention of sodium and chloride depletion (e.g., hyponatremia, hypochloremia),Fluid resuscitation in hypovolemia or shock,Diluent for intravenous medications,Maintenance of intravenous lines (saline locks),Irrigation of wounds and body cavities (e.g., during surgery),Management of hypercalcemia (promotes calcivresis),Diagnostic agent (e.g., in bronchoprovocation testing)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous: 0.9% sodium chloride (normal saline) infusion at 50-100 m L/hour for maintenance; dose depends on indication (e.g., 500-1000 m L bolus for hypovolemia). Maximum rate: 1 L/hour in emergencies.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Variable and distribution-dependent; for acute changes, distribution half-life ~20 minutes; terminal half-life ~8-12 hours for total body sodium adjustment, clinically relevant for electrolyte correction
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Sodium and chloride ions are not metabolized; they are absorbed and distributed throughout the body, then excreted primarily by the kidneys. Regulation occurs via renal tubular reabsorption and excretion under hormonal control (e.g., aldosterone, ADH).
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily renal (>90%) via glomerular filtration and tubular reabsorption; negligible biliary/fecal elimination (<1%)
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Negligible (<1%); not significantly protein-bound
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Approximately 0.6-0.7 L/kg (total body water); expands with extracellular fluid volume expansion
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral: 100% (passive absorption, no first-pass metabolism); intravenous: 100%
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No dose adjustment required; use with caution in severe renal impairment due to fluid overload risk.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No dose adjustment required; monitor for fluid overload in cirrhosis with ascites.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous: Maintenance 100-120 m L/kg/day for first 10 kg, plus 50 m L/kg/day for next 10 kg, plus 20 m L/kg/day for each kg above 20; bolus 10-20 m L/kg over 30-60 minutes for hypovolemia.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Use lower infusion rates (e.g., 25-50 m L/hour maintenance) and monitor for fluid overload; adjust based on renal function and cardiovascular status.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA black box warning for sodium chloride.
None
Use with caution in patients with heart failure, renal impairment, cirrhosis with ascites, or edema (risk of fluid overload),Monitor serum electrolytes, fluid balance, and renal function during prolonged therapy,Avoid rapid infusion of large volumes, especially in patients with compromised cardiovascular or renal function,Use with caution in patients with hypertension (sodium load may increase blood pressure),Do not use solutions containing preservatives for irrigation of certain tissues (e.g., ophthalmic use),Risk of hypernatremia and hyperchloremia with excessive administration
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypernatremia or hyperchloremia,Fluid overload (e.g., pulmonary edema, severe congestive heart failure),Severe renal impairment with oliguria or anuria (unless dialysis is being performed),Patients with elevated lactate levels (e.g., lactic acidosis) when used as a large volume resuscitation fluid (due to risk of hyperchloremic acidosis)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid high-sodium foods (e.g., processed meats, canned soups, salty snacks) if receiving sodium chloride for hyponatremia or fluid management. No specific food interactions, but dietary sodium intake should be consistent with prescribed electrolyte goals.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Sodium chloride is an essential electrolyte and not teratogenic at physiological doses. No fetal risks identified in trimester 1, 2, or 3 when used appropriately. Excessive doses may cause maternal electrolyte imbalance, potentially affecting fetal homeostasis.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Sodium chloride is a normal component of breast milk. No adverse effects expected at therapeutic doses. M/P ratio not applicable as it is an endogenous substance. Compatible with breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No dose adjustment required for normal replacement therapy. Pregnancy-induced plasma volume expansion may require higher maintenance doses in conditions like hypovolemia. In preeclampsia or eclampsia, careful monitoring and adjustment to avoid fluid overload. No specific pharmacokinetic changes necessitating dose alteration for basal requirements.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Administer 0.9% sodium chloride for volume expansion in hypovolemic patients; use with caution in heart failure or renal impairment due to risk of fluid overload. Hypertonic saline (3%) is reserved for severe hyponatremia with neurological symptoms; correct sodium slowly to avoid osmotic demyelination. Check serum sodium and osmolality before repeated doses.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Sodium chloride is salt; your dose depends on your blood sodium levels and hydration status.,You may experience swelling if you receive too much fluid; report shortness of breath or leg swelling.,This solution may be given through a vein; tell your nurse if you feel burning or pain at the IV site.,Do not consume extra salt in your diet unless directed; follow any dietary sodium restrictions from your doctor.,Monitor your weight daily if on long-term therapy, as sudden weight gain may indicate fluid retention.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE is a Electrolyte that works by Sodium chloride dissociates in body fluids into sodium and chloride ions, which are major determinants of extracellular fluid osmolality and volume. It maintains electrolyte balance, nerve impulse transmission, and muscle contraction.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE is: Intravenous: 0.9% sodium chloride (normal saline) infusion at 50-100 m L/hour for maintenance; dose depends on indication (e.g., 500-1000 m L bolus for hypovolemia). Maximum rate: 1 L/hour in emergencies.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE is classified as Category A/B. Sodium chloride is an essential electrolyte and not teratogenic at physiological doses. No fetal risks identified in trimester 1, 2, or 3 when used appropriately. Excessive doses m. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.